FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, Myeloma14 May 2020
MPE webinar on the impact of myeloma and AL amyloidosis in carers. What are the issues and challenges?AL amyloidosis, MPE, Myeloma8 May 2020
